Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines for central nervous system diseases, serving patients through healthcare providers and selling primarily to pharmaceutical wholesalers, specialty pharmacies and distributors. Its marketed portfolio addresses ADHD,… From the company’s description.
Over the twelve months to Sep 30, 2026, Supernus Pharmaceuticals, Inc. reported revenue of $865.11M, up 26.9% from a year earlier, and a net loss of $43.86M. Its operating margin was −5.7%, and operations generated $88.18M in cash. In fiscal 2025, it reported revenue of $718.95M, up 8.6% from fiscal 2024, and a net loss of $38.55M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Supernus Pharmaceuticals, Inc. does
In the company’s own words
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes medicines for central nervous system diseases, serving patients through healthcare providers and selling primarily to pharmaceutical wholesalers, specialty pharmacies and distributors. Its marketed portfolio addresses ADHD, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea, with products including Qelbree, GOCOVRI, APOKYN, ONAPGO, ZURZUVAE, Trokendi XR, Oxtellar XR, XADAGO and MYOBLOC. Supernus markets products through its U.S. sales organization and collaborates with pharmaceutical companies on commercialization outside the United States; it also develops CNS drug candidates, including treatments under clinical investigation for epilepsy and depression. The company relies on contract manufacturers for its commercial products and product candidates. Its 2025 acquisition of Sage Therapeutics added rights to ZURZUVAE, which Supernus commercializes in the United States with Biogen, and expanded its neuroscience portfolio. Supernus began operations in 2005 after acquiring substantially all assets of Shire Laboratories, and became publicly traded in 2012. Its website is https://www.supernus.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- ROCKVILLE, MD
- Fiscal year end
- December
- CIK
- 1356576
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Supernus Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Supernus Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Supernus Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Supernus Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Supernus Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”